KMT2A and acute myeloid leukemia: However, next-generation sequencing (NGS) panels have become part of the current standard-of-care testing for AML, as they can enable comprehensive molecular profiling and risk prognostication for sequence variants, in addition to identifying KMT2A-PTDs [16,25,26,27,28,29,30].